Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > The breadcrumbs I see in the IR

<< Previous

Bullboard Posts

Next >>

Comment by MMABStraderon Oct 07, 2022 1:02pm

192 Views

Post# 35012630

RE:RE:RE:The breadcrumbs I see in the IR

I believe Spectral is being extremely selective in treating patients with PMX in order to assure an outcome that is positive. I believe the faster enrollment rate for the Euphrates trial was easier and quicker because the focus was more on treating patients closer to 9 using the EEA diagnostic tool. Those patients had nothing to lose since they were at death's door. For most patients at 9 or 9 plus they had nothing to lose and everything to gain by getting the PMX treatment.

Hopefully, the cautious selectivity of patient participants in the current test will lead to a better end result which will lead to a greater value for PMX, Spectral, etc.

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta